Ovulation product cycles to FTC, FDA
This article was originally published in The Tan Sheet
Executive Summary
Advertising for Ovulex Fertility Enhancement has been referred to FTC and FDA after AMI, Inc/Selmedica Healthcare declined to participate in NAD's self-regulatory forum, watchdog group says Dec. 6. NAD was troubled by claims that the product will "increase your chances of conception by 1870% in less than 10 days," and "women who use the Ovulex plan are up to 1800% more likely to conceive," which were found during the group's routine monitoring program...